Fractyl Health has reported positive six-month topline results from the pivotal cohort of REMAIN-1, a randomized, double-blind, sham-controlled study of its Revita DMR System in adults with obesity who had already lost weight on tirzepatide.

Tirzepatide is sold as Mounjaro and Zepbound, and the problem the trial targets is the one every GLP-1 prescriber now talks about: what happens when people stop. Revita is not a drug but a procedure, an endoscopic ablation of part of the duodenal lining, and the company is testing whether it can hold weight loss in place after the injections end.

Key results

In the modified intention-to-treat population of 308 participants, Fractyl says Revita recipients maintained roughly 80% of their GLP-1 induced weight loss at six months, against 67% in the sham group. Least-squares mean weight regain was 5.1% versus 8.2%, which the company reports at p=0.0023.

A second figure is doing a lot of the promotional work: 32% of Revita participants were weight stable or still losing at six months, versus 18% for sham. That one is post hoc with a nominal p value of 0.020, and the company labels it as such.

The dose-response signal

Fractyl also reports a length-dependent effect in post hoc analysis, with ablations of 20 cm or more showing mean regain of 3.8% against 8.2% for sham, a 53% reduction at a nominal p=0.003. A dose response is the kind of internal consistency that makes a result more believable, and it is also exactly the kind of subgroup slice that looks strongest before anyone has pre-specified it.

On safety, the company says Revita was generally well tolerated with no device-related or procedure-related serious adverse events as of the 24 September 2026 data cut-off.

Where the caveats are

Everything above is company topline, not a peer-reviewed paper, and the headline endpoint is six months in a question that is really about years. Twelve-month data is expected in Q1 2027.

What happens next

Revita holds FDA Breakthrough Device designation, and Fractyl plans a De Novo marketing submission in late Q4 2026, citing a potential U.S. launch in early 2028 with CPT code 1122T effective 1 January 2027. Whether the six-month gap survives to twelve is the number worth waiting for.